Estimating disability-adjusted life years for breast cancer and the impact of screening in female populations in China, 2015–2030: an exploratory prevalence-based analysis applying local weights

Xin-Xin Yan1†, Juan Zhu1,2†, Yan-Jie Li1†, Meng-Di Cao1†, Xin Wang1, Hong Wang1, Cheng-Cheng Liu1, Jing Wang3, Yang Li4* and Ju-Fang Shi1*

Abstract

Background: Most cancer disability-adjusted life year (DALY) studies worldwide have used broad, generic disability weights (DWs); however, differences exist among populations and types of cancers. Using breast cancer as example, this study aimed to estimate the population-level DALYs in females in China and the impact of screening as well as applying local DWs.

Methods: Using multisource data, a prevalence-based model was constructed. (1) Overall years lived with disability (YLDs) were estimated by using numbers of prevalence cases, stage-specific proportions, and local DWs for breast cancer. Numbers of females and new breast cancer cases as well as local survival rates were used to calculate the number of prevalence cases. (2) Years of life lost (YLLs) were estimated using breast cancer mortality rates, female numbers and standard life expectancies. (3) The prevalence of and mortality due to breast cancer and associated DALYs from 2020 to 2030 were predicted using Joinpoint regression. (4) Assumptions considered for screening predictions included expanding coverage, reducing mortality due to breast cancer and improving early-stage proportion for breast cancer.

Results: In Chinese females, the estimated number of breast cancer DALYs was 2251.5 thousand (of 17.3% were YLDs) in 2015, which is predicted to increase by 26.7% (60.3% among those aged ≥ 65 years) in 2030 (2852.8...
Introduction

Increasing attention has been given to disability-adjusted life years (DALYs) [1]. DALYs have been regarded as a common indicator of burdens of disease in many countries [2]; DALYs consider both the burden of death (years of life lost [YLLs] due to premature death) and the years lived with disability (YLDs). Population-specific disability weights (DWs) play an important role in the accuracy of YLDs estimations [3, 4]. The Global Burden of Disease Study (GBD), an influential global study, evaluated the DALYs associated with more than 300 diseases and injuries. Early DWs of GBD were obtained from five countries (such as Bangladesh), and since 2013, data from four European countries have been added [5]. However, it can still not distinguish the DWs and YLDs with high precision in the context of different social and cultural backgrounds [3, 4]. Population-specific breast cancer DWs are of great value in DALYs estimations at the population level in China and worldwide.

In 2015, 304 thousand new cases of female breast cancer occurred in China [6], ranking first among female cancers. With the aging of the population, the burden of breast cancer would keep an upward trend [7, 8]. The 5-year survival rate among female breast cancer patients in China was 82.0% between 2012 and 2015. Compared with that of advanced-stage breast cancer, the prognosis of early-stage breast cancer is better [9], and the cost of diagnosis and treatment was lower [10, 11]. Breast cancer screening is becoming an essential strategy for cancer prevention and control. A national screening program for breast cancer in Australia has observed a decline in the burden of breast cancer [3]. A recent systematic review including 27 global studies showed a 22% reduction in breast cancer mortality after carrying out breast cancer screening for approximately a decade [12]. Females have benefited greatly from screening programs. The central government has proposed the “Healthy China initiative (2019–2030)” that the coverages of breast cancer screening in rural areas are expected to reach 80% and 90% by 2022 and 2030, respectively [13].

Overall design

Using available multisource data (including published literature, open databases and local studies), a prevalence-based model was built [5]. Then, Joinpoint regression was applied to predict the prevalence and mortality rates of breast cancer and associated DALYs from 2020 to 2030. Finally, sensitivity analyses were performed to evaluate the impacts of demographics, DWs and screening parameters. The analysis indicators were DALYs and the age-standardized DALY rate (ASDR) considering Segis’ world standardized population. The overall methodology was shown in Fig. 1.

Data sources

Data on the incidence, mortality, and DALYs rates of breast cancer in China from 2006 to 2015 were extracted from the Chinese cancer registry annual reports (2009–2018) [20–29]. A national cancer surveillance network exists in China, and cancer registration is carried out in all provinces. In 2015, the national cancer surveillance network was expanded to include 501 cancer registries and covered 387,872,825 people, including 197,211,672 males and 190,661,153 females, accounting for 28.22% of the national population. All patients included in the
Fig. 1 The overall methodology

Death cases of breast cancer estimation
\[ \text{DC}_a = \text{DR}_a \times \text{Pop}_a \]
\[ \text{DR}_a: \text{Age-specific mortality rate of breast cancer} \]
\[ \text{Pop}_a: \text{Age-specific number of females population} \]

Total prevalence cases of breast cancer estimation
\[ \text{PC}_a = \sum_{n=0}^{9} \text{IR}_{a,n} \times \text{Pop}_{a,n} \times \text{Sur}_{a,n} \]
\[ \text{See the formula below} \]

Parameters selection of breast cancer clinical stages (I-IV) proportions
Based on a multicenter hospital-based clinical epidemiologic survey

Estimation of each clinical stage-specific prevalence cases of breast cancer
\[ \text{PC}_c = \text{PC} \times \text{SP}_c \]
\[ \text{PC}: \text{Cumulative prevalence cases of breast cancer in 10 years} \]
\[ \text{SP}_c: \text{Proportion of breast cancer in different clinical stages} \]

Breast cancer clinical stage-specific DWs
Methods: health utility score_0 - health utility score_1
Data source: A national multicenter hospital-based survey

YLLs estimation
\[ \text{YLLs} = \sum \text{DC}_a \times \text{SE}_a \]
\[ \text{DC}_a: \text{Age-specific death cases} \]
\[ \text{SE}_a: \text{Age-specific standard life expectancy} \]

YLDs estimation
\[ \text{YLDs} = \sum \text{PC}_c \times \text{DW}_c \]
\[ \text{PC}_c: \text{Stage-specific prevalence cases of breast cancer} \]
\[ \text{DW}_c: \text{Stage-specific disability weights of breast cancer} \]

Current status estimation: Total DALYs for breast cancer in China, 2015
\[ \text{DALYs} = \text{YLLs} + \text{YLDs} \]
Core indicators: Total DALYs, age-standardized DALY rate, rate of change in different years and age groups after breast cancer screening intervention

Future Prediction: Total DALYs for breast cancer in China, 2020-2030
Joinpoint regression was used to analyze the local incidence and mortality rates of breast cancer over the past 2005-2015 to obtain annual growth rates to estimate the prevalence and mortality rates by 2020, 2025, and 2030.

Prevalence rate: \[ \text{PrePR}_a = \text{PR}_{2015} \times (1 + \text{APC}_{2015})^{t-2015} \]
- \[ \text{PR}_{2015}: \text{Breast cancer prevalence rate in China, 2015} \]
- \[ \text{APC}_{2015}: \text{Annual change rate of breast cancer prevalence from 2005 to 2015} \]

Mortality rate: \[ \text{PreDR}_a = \text{DR}_{2015} \times (1 + \text{APC}_{2015})^{t-2015} \]
- \[ \text{DR}_{2015}: \text{Breast cancer mortality rate in China, 2015} \]
- \[ \text{APC}_{2015}: \text{Annual change rate of breast cancer mortality from 2005 to 2015} \]

\[ ^* \text{Formula for the estimation of the prevalence cases of breast cancer as follows:} \]
- \[ a: \text{Age group (5-, 10-, ……, 85+)} \]
- \[ \text{PC}_{a, n}: \text{Age-specific number of 10 years prevalence cases of breast cancer in n(0-9) years ago} \]
- \[ \text{Pop}_{a, n}: \text{Age-specific number of female population in n(0-9) years ago} \]
- \[ \text{Sur}_{a, n}: \text{Age-specific survival rate of breast cancer in n(0-9) years ago} \]
- \[ n=0 \text{means the current year} \]

\[ ^{**} \text{The screening can impact breast cancer at multiple levels, such as altering clinical stages of breast cancer prevalence, reducing mortality of breast cancer, and the effect of expanding screening coverage. The impact on the reduction of breast cancer mortality with screening was estimated using the following formula:} \]
\[ \text{S-DC}_a = \sum \text{DC}_a \times \sum \text{Cov}_a \times (1 - \text{Red}_a) \]
- \[ \text{S-DC}_a: \text{Age-specific death cases after screening} \]
- \[ \text{DC}_a: \text{Age-specific death cases} \]
- \[ k: \text{keeping stable at the same screening coverage for K (5,10,15) years} \]
- \[ \text{Cov}_a: \text{Maintaining same screening coverage for k years} \]
- \[ \text{Red}_a: \text{Reduction of breast cancer mortality for k years} \]

\[ ^{***} \text{Since local prevalence information was unavailable, considering that the breast cancer incidence and prevalence rate in the past 20 years was highly linearly correlated with the annual change according to the GBD data (for both Chinese and global females, the correlation coefficient was 0.99, p<0.001). Therefore, the annual change rate of incidence reported by local cancer was used as the replacement value of the prevalence rate.} \]

This chart mainly presents the base-case analysis method and main considerations. More sensitivity analysis related parameters selection and data sources were shown in Additional files 1 and 2.
registry had invasive cases, and all cancer cases were coded according to the International Classification of Diseases for Oncology, 3rd revision (ICD-O-3), and the International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10). Provincial cancer registry centers are responsible for collecting, evaluating, and publishing provincial cancer statistics (including incidence, mortality and survival). All hospitals, medical and health institutions in administrative regions are required to submit cancer records to local cancer registries; this data is then submitted to the national cancer registry [29].

Demographic data were obtained from officially published reports, including China Population Statistics Yearbook [30] and World Population Prospects 2019 [31], which contain age-specific demographic information. Female standardized life expectancies were obtained from the GBD 2015 [32] and World Population Prospects 2019 [31]. Epidemiological parameters of breast cancer (incidence rate, mortality rate and survival rate) were obtained from the Chinese Cancer Register annual report [20–29] and the previous study [9]. DWs were obtained by converting the health utility values (calculated by “health utility scorenormal-health utility scorebreast cancer”) [18, 19], with the data of utilities obtained from two Chinese studies [15, 18, 19, 33]. This method was the most commonly used method summarized by a previous systematic review (five calculation measures in total) [17]. The proportions of clinical stages were obtained from national research in China [34, 35]. The detailed parameter sources and methods were shown in Additional files 1 and 2.

**Parameters of breast cancer screening**

Previous studies have shown that breast cancer screening plays a vital role in disease progression and the distribution of disease factors, such as the distributions of clinical stage and mortality. (1) The distributions of clinical stages were calculated from base-case data obtained from a multicenter hospital-based clinical epidemiologic survey among females who did not undergo screening in 2015; the population included 4211 breast cancer patients from 7 provinces in China (stage I: 19.2%) [35]. The data of Chinese females who underwent screening in 2015 were obtained from the “Central Financial Transfer Payment Project-Chinese Women Breast Cancer Screening Study”, which included 0.4 million women from 30 provinces in China (stage I: 35.9%) [34]; (2) The ten-year reduction in breast cancer mortality after screening was calculated from base-case data from a recent global meta-analysis (including 27 studies), which reported that the integrated mortality reduction rate was 22% (95% confidence interval [CI]: 18–25%)[12]. A linear hypothesis that the breast cancer mortality after screening five years and 15 years declined by 11% and 33%, respectively, was made. According to the results of the global meta-analysis and hypothesized data, “42%” was the maximum value of the included studies in the meta-analysis; since there were differences among the included studies, the sensitivity analyses tried the values of 25% (upper 95% CI of the meta-analysis results), 15%, and 5% in turn. (3) The coverage of breast cancer screening: According to the population-level screening coverage rates reported in the previous studies in China, breast cancer screening rates were 25.7% in women aged 35–64 years in 2015, and increased approximately 1% per year from 2013 to 2015 [36, 37]. Accordingly, the coverage rates (at the individual level) of breast cancer screening in Chinese females were estimated to be 30.7%, 35.7%, and 40.7% for 2020, 2025, and 2030, respectively.

**YLDs estimation**

The incidence rates of breast cancer from 2006 to 2015 in China were derived from the annual report of Chinese cancer register[20–29] and female population statistics[30], using numbers of females and new breast cancer cases, and local survival rates, to obtain the overall numbers of prevalence cases in 2015 according to the prevalence calculation formula[38] (see Fig. 1 Formula 1). Then using local data(detailed year- and age-specific data were shown in Additional file 3) on clinical stage-specific(I-IV) proportions for breast cancer and DWs to calculate overall YLDs. Survival rates were based on the 5-year survival rate of breast cancer in 2012–2015 in China (the best available local data at present) [9] and the survival rate ratios between age groups calculated from Surveillance, Epidemiology, and End Results (SEER) 5-year relative survival rates [39]. We extrapolated the age-specific 1- to 9-year survival parameters of breast cancer in China (detailed year- and age-specific data were shown in Additional file 3). The base-case DWs for different clinical stages (I–IV) were calculated as “health utility scorenormal-health utility scorebreast cancer” which was the most commonly used method in previous systematic review [17–19]. The health utility scores were extracted from two previous Chinese articles [15, 34].

**YLLs estimation**

Total YLLs were estimated using mortality rates of breast cancer, female numbers and standard life expectancies [29, 30, 32]. The standard life expectancy (84.2 years) estimated by the GBD 2015 was used as the base-case parameter for external comparison [32]. Detailed year- and age-specific life expectancy data were shown in Additional file 4. According to the standard life expectancy in 2015 reported by the GBD 2015 and in 2050.
reported by the World Health Organization (WHO) [40], the standard life expectancy in 2030 was estimated linearly, detailed age-specific data were shown in Additional file 4.

Predicting DALYs for 2020–2030
The incidence (strong linear correlation with the annual change rate of prevalence, correlation coefficient \(= 0.9, p < 0.001\)) and mortality rates of breast cancer were derived from the annual reports of Chinese cancer register covering the past several years [20–29]. A Joinpoint regression model (Joinpoint Regression Program 4.7.0.0) was used to calculate annual growth rates of prevalence and mortality rates (1.5% and 1.9%, respectively) and to predict the corresponding rates in 2020, 2025, and 2030 (assumption: there would be linear increases in the age-specific prevalence and mortality rates from 2015 to 2030). Standard life expectancies (84.2 years) from the GBD 2015 [32] and WHO 2050 (89.4 years) [40] were applied to the model. The standard life expectancies in 2020, 2025, and 2030 (84.9 years, 85.7 years, and 86.4 years, respectively) were estimated linearly. Changes in YLLs, YLDs, and DALYs were predicted for 2020, 2025, and 2030 using a similar approach. The formula was shown in Fig. 1.

Sensitivity analysis
The sensitivity analysis was based on the single factor analysis with replacing parameters. Limited by the availability of detailed data in China, some parameters were derived from assumptions and foreign studies. A series of sensitivity analyses were carried out for DWs, demographic, and screening parameters associated with breast cancer. Detailed sensitivity analysis factors were shown in Additional files 1 and 2.

Results
DALYs in 2015
In females in China, 2251.5 thousand breast cancer DALYs were estimated in 2015 (of 82.7% were YLLs: 1861.0 thousand; of 17.3% were YLDs: 390.5 thousand), and the corresponding results reported by the GBD [5] was 2527.0 thousand (of 8.2% were YLDs). The ASDR was 227.6/100,000. Among the overall DALYs, 1819.3 thousand were in breast cancer patients aged < 65 years and 432.3 thousand were in those aged ≥65 years, accounting for 80.8% and 19.2% of the total DALYs, respectively. Additional details are provided in Fig. 2.

DALYs in 2020–2030
If breast cancer screening coverage (25.7%) remains unchanged, the number of breast cancer DALYs in females are expected to increase by 26.7% (60.3% among those aged ≥65 years; 18.6% among those aged < 65 years) in 2030 (2852.8 thousand, ASDR: 244.9/100,000). The YLLs (2385.9 thousand, 203.5/100,000) and YLDs (466.9 thousand, 41.4/100,000) would increase by 28.2% and 19.6%, respectively. The DALYs of breast cancer in females aged < 65 years and ≥65 years would increase 18.6% and 60.3%, respectively. The DALYs in the ≥65 years age group would account for 24.3% of the total DALY burden of breast cancer in 2030. Further details are provided in Fig. 2.

Alternatively, if the individual-level coverage of breast screening expands from 25.7% in 2015 to 40.7% in 2030 (deduced from the "Healthy China Initiative, 2019–2030"), the overall number of breast cancer DALYs (2816.1 thousand) would decrease by 1.3% in the whole female population, compared with the value in the same year without the expansion of coverage; the DALYs would decrease by 1.5% among the screened age group (35–74 years). Additional predicted DALYs and age-standardized results are provided in Fig. 3.

Sensitivity analysis of DWs
The sensitivity analysis found that using local DWs would change ~10% of base-case values. The results showed that the approach based on “1-visual analog scale (VAS) score/100” [17–19] had the most significant impact on breast cancer DALYs (increase 10.5%) among the six DWs approaches in 2015. Compared with the base-case DALYs in 2015, the corresponding DALYs using the DWs in the GBD [5] (diagnosis and primary therapy phase: 0.288, controlled phase: 0.049, metastatic phase: 0.451 and terminal phase: 0.569) decreased by 5.0%. The above-mentioned change in the DALYs would be less than 10% in 2030. Further details are provided in Fig. 4A.

Sensitivity analysis of other key parameters
Sensitivity analyses of demographic and screening parameters showed that: (1) Life expectancy had a strong influence on the DALYs regardless of the years (decreases 16.4% in 2015 and 17.5% in 2030); (2) using predicted prevalence and mortality rates from various databases may change the predicted DALYs in 2030 by 3.9% to 14.0%; and (3) if breast cancer screening coverage expands to 55% in 2030, the DALYs would decrease by 2.5% (among those aged 35–74 years: 3.0%). Further findings regarding impacts from other parameters, including the reduction in cancer mortality due to screening, screening ages, and distributions of cancer clinical stages, are presented in Fig. 4.
Fig. 2 Estimated population-level DALYs attributable to breast cancer in China, 2015–2030. A Age-standardized DALY rate (rate of change, compared with the value in 2015, %). B Overall number of DALYs (rate of change, %). C Age-specific number of DALYs (rate of change, %)
Compared with other disease burden indicators, such as incidence and mortality, DALYs are reported in relatively few studies, and even fewer studies have reported DALYs in the Chinese population [7]. This study was the first attempt to use local DWs to calculate the DALYs burden based on the breast cancer prevalence in 2015 among Chinese females, predict the breast cancer DALYs in 2030 under different screening scenarios and estimate the impact of the application of local, detailed DWs. The main findings are as follows: the estimated number of breast cancer DALYs in China was lower overall, but higher in the proportion of YLDs than the number in GBD, suggesting the importance of considering population-specific parameters. (1) A total of 2527.0 thousand breast cancer DALYs in 2015 in China were reported in the GBD [5]. The lower estimate in this study may be explained by the use of local data, including local breast cancer mortality rates, which were lower than those in the GBD [20–29] as well as the Chinese female population [30]. The DALYs estimates were even lower when using the population data reported by the United Nations. (2) YLDs accounted for 17.3% of DALYs, which was higher than that (8.2%) reported in the GBD. This was related to the fact that local DWs values were higher than the DW values in the GBD [5]. Using the DWs for the diagnosis and primary therapy phase, the controlled phase, the metastatic phase and the terminal phase from the GBD [5], the proportion of YLDs decreased to 13.0% in the study, which was close to the reported value in the GBD. Differences were also observed when considering different cancer stage types and the distribution of each stage. The cancer stages in the GBD did not match the typical clinical stages in the Chinese population, so the impact could not be estimated.

**Discussion**

Fig. 3 Predicted impact of screening on population-level DALYs attributable to breast cancer in China, 2020–2030. A age-standardized DALY rates in all age groups (rate of change, compared with the value in the same year with no expansion of screening coverage, %). B Age-standardized DALY rate in the 35–74 years age group (rate of change, %). C Overall numbers of DALYs in all age groups (rate of change, %). D Number of DALYs in the 35–74 years age group (rate of change, %). a Unexpanded screening coverage: always assumed to be 25.7% (individual level) from 2015 to 2030. b Expanded screening coverage: estimated to be 30.7% in 2020, 35.7% in 2025 and 40.7% in 2030 (calculated using data from published literature, deduced from the county-level target in the “Healthy China Initiative, 2019–2030”)

A total of 2527.0 thousand breast cancer DALYs in 2015 in China were reported in the GBD [5]. The lower estimate in this study may be explained by the use of local data, including local breast cancer mortality rates, which were lower than those in the GBD [20–29] as well as the Chinese female population [30]. The DALYs estimates were even lower when using the population data reported by the United Nations. The cancer stages in the GBD did not match the typical clinical stages in the Chinese population, so the impact could not be estimated.
# Sensitivity analyses

## A. Impact of DWs on the overall number of DALYs in all age groups

### Base-case in 2015

| Parameters | DALYs, thousand | Percentage change compared with base-case (%) |
|------------|-----------------|---------------------------------------------|
| DWs: the lower bound of 95% CI of the base-case DWs | 2214.3 | -1.7% |
| DWs: 1- health utility scorebreast cancer (a multicenter survey) | 2365.3 | 5.1% |
| DWs: 1-VAS score/100 (a multicenter survey) | 2486.9 | 10.5% |
| DWs: health utility scorebreast cancer-health utility scorebreast cancer (a Meta-analysis) | 2317.9 | 2.9% |
| DWs: 1- health utility scorebreast cancer (a Meta-analysis) | 2433.5 | 8.1% |
| DWs: GBD 2015 | 2139.2 | -5.0% |

### Base-case in 2030

| Parameters | DALYs, thousand | Percentage change compared with base-case (%) |
|------------|-----------------|---------------------------------------------|
| DWs: the lower bound of 95% CI of the base-case DWs | 2808.3 | -1.6% |
| DWs: 1- health utility scorebreast cancer (a multicenter survey) | 2988.9 | 4.8% |
| DWs: 1-VAS score/100 (a multicenter survey) | 3134.2 | 9.9% |
| DWs: health utility scorebreast cancer-health utility scorebreast cancer (a Meta-analysis) | 2932.2 | 2.8% |
| DWs: 1- health utility scorebreast cancer (a Meta-analysis) | 3070.4 | 7.6% |
| DWs: GBD 2015 | 2718.5 | -4.7% |

## B. Impact of demographic parameters on the overall number of DALYs in all age groups

### Base-case in 2015

| Parameters | DALYs, thousand | Percentage change compared with base-case (%) |
|------------|-----------------|---------------------------------------------|
| Number of female population: United Nations website | 2188.2 | -2.8% |
| Survival data of female breast cancer survival: developed countries | 2268.2 | 0.7% |
| Standardized life expectancy of female: 2015 Chinese female life expectancy (United Nations estimation) | 1881.3 | -16.4% |

### Base-case in 2030

| Parameters | DALYs, thousand | Percentage change compared with base-case (%) |
|------------|-----------------|---------------------------------------------|
| Survival data of female breast cancer survival: developed countries | 2874.1 | 0.7% |
| Standardized life expectancy of female: 2015 Chinese female life expectancy (United Nations estimation) | 2356.0 | -17.4% |
| Predicted prevalence of female breast cancer: GBD website | 2963.2 | 3.9% |
| Predicted mortality of female breast cancer: GBD website | 3143.1 | 10.2% |
| Predicted prevalence and mortality of female breast cancer: GBD website | 3253.5 | 14.0% |

## C. Impact of breast cancer screening parameters on the overall number of DALYs in all age groups in 2030

### Base-case in 2030

| Parameters | DALYs, thousand | Percentage change compared with base-case (%) |
|------------|-----------------|---------------------------------------------|
| Screening coverage in 2030: 55.0% (Australia national breast cancer screening project) | 2781.1 | -2.5% |
| Screening age: 40-74 (national public health program recommendation) | 2819.0 | -1.2% |
| Screening age: 50-69 (ARIC recommendation) | 2863.0 | 0.4% |
| Distributions of clinical stages of breast cancer screening: China Hong Kong Cancer Registry | 2895.6 | 1.5% |
| Reduction of mortality of breast cancer screening: 5% | 2984.2 | 4.6% |
| Reduction of mortality of breast cancer screening: 15% | 2885.3 | 1.1% |
| Reduction of mortality of breast cancer screening: 25% (the upper bound of 95% CI of the global Meta-analysis) | 2786.4 | -2.3% |
| Reduction of mortality of breast cancer screening: 42% (the maximum value of a global Meta-analysis) | 2618.3 | -8.2% |

## D. Impact of breast cancer screening parameters on the overall number of DALYs in 35-74 years age group in 2030

### Base-case in 2030

| Parameters | DALYs, thousand | Percentage change compared with base-case (%) |
|------------|-----------------|---------------------------------------------|
| Screening coverage in 2015: 26.5% (the fifth National Health Services Survey in China) | 2301.6 | -3.0% |
| Distributions of clinical stages of breast cancer screening: China Hong Kong Cancer Registry | 2339.5 | -1.4% |
| Reduction of mortality of breast cancer screening: 5% | 2504.7 | 5.5% |
| Reduction of mortality of breast cancer screening: 15% | 2405.8 | 1.4% |
| Reduction of mortality of breast cancer screening: 25% (the upper bound of 95% CI of the global Meta-analysis) | 2306.9 | -2.8% |
| Reduction of mortality of breast cancer screening: 42% (the maximum value of a global Meta-analysis) | 2138.8 | -9.9% |

**Fig. 4** Sensitivity analyses. A Impacts of DWs on the overall numbers of DALYs in all age groups. B Impacts of demographic parameters on the overall numbers of DALYs in all age groups. C Impacts of breast cancer screening-related parameters on the overall numbers of DALYs in all age groups in 2030. D Impacts of breast cancer screening-related parameters on the overall number of DALYs in the 35-74 years age group in 2030.
This study suggested that if the screening coverage remains unchanged, the DALYs will increase by 26.7% in 2030, especially among the elderly population. The predicted breast cancer incidence and mortality from International Agency for Research on Cancer among Chinese females from 2020 to 2035 (increase 15.0% and 38.1%, respectively) [41] were consistent with those in our study. This study also found that if coverage expands to 40.7% in 2030, the DALYs would decrease by 1.5% among females aged 35–74 years, which was less than expected. One possible explanation is that breast cancer screening slightly impacts the reduction in mortality for a short duration (approximately 20% for ten years), and this study was limited by the approximately ten-year observation. In other words, even with ideally complete coverage in 2020, there would be an approximately 20% reduction in mortality by 2030. However, the breast cancer screening coverage in China is still gradually expanding under government promotion. Considering the number of the Chinese population, it cannot achieve full coverage in the near future. Therefore, the population-based breast cancer screening and other secondary prevention strategies need long-term and robust promotion.

Mainly enabled by detailed DWs associated with cancer patients in China, along with some integrated key demographic parameters and breast cancer and screening parameters, as well as the governmental goals for cancer control, the current prevalence-based analysis is, to the best of our knowledge, the most detailed exploratory DALY estimation focusing on breast cancer, and this approach could potentially be extended to broader cancer types and diseases. The findings also suggest the importance of applying the population- and cancer-specific DWs in estimating the DALYs. DWs should be given more attention in future related research and evaluations, in both China and worldwide.

The current study has several limitations. (1) Methodology: One of the purposes of our study was to provide a relatively simple method for calculating DALYs based on locally available parameters. Although the simple DALY model based on prevalence was relatively feasible, more accurate estimations could not be achieved. For example, precancerous lesions and their influence on the incidence were not considered, and the prognoses of different clinical stages were not distinguished. Additionally, the health utility values associated with these disease statuses have not been reported. (2) Data of local parameters were unavailable: Some data on factors such as breast cancer prevalence and survival rates, screening coverage and outcomes were hypothesized or indirectly assumed in this study; this may increase the instability of the results, although sensitivity analyses were performed. In future studies, additional available parameters will be summarized to support our calculation. (3) Short prediction duration: a larger reduction in the DALYs is expected to be observed when more robust local data are available in the future, with long-term projections. In the future study, we will use complex models to calculate DALYs more accurately.

Conclusions
The global platform (GBD) data are a convenient and comparable resource for cancer prevention and control analyses worldwide. Population-level and population-specific DALYs are of great necessity. Due to promotion by the government and the development of academic research, several large-scale screening intervention projects for secondary cancer prevention have been gradually initiated. The localized disease burden estimate is particularly helpful and meaningful to the evaluation of innovative interventions and the development of prompt and accurate guidance for decision-makers. Future research directions should be considered: (1) according to the definitions of cancer stages in the GBD [5], and matching and quantifying local DWs in China is a promising approach; (2) further studies could optimize the DALYs estimation based on prevalence, and carry out more accurate calculations using life tables, Markov multi-queue models and other models.

Abbreviations
DALYs: Disability-adjusted life years; YLDs: Years lived with disability; YLLs: Years of life lost; DWs: Disability weights; GBD: Global burden of disease study; 95% CI: 95% confidence interval.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12963-022-00296-1.

Acknowledgements
The authors thank the GBD study for open access to the web information.

Author contributions
XXY contributed to information curation, methodology, data analysis, validation, visualization and writing the manuscript. JZ contributed to information curation, methodology, data analysis, validation, and writing the manuscript. YJL contributed to information curation and writing the manuscript. MDC contributed to information curation and writing the manuscript. XW contributed to reviewing preliminary results, resource and informing subsequent analysis. HW contributed to reviewing preliminary results and informing subsequent analysis. CCL contributed to reviewing preliminary results and

Additional file 1: Demographic, breast cancer epidemiological and screening factors of the female populations in China.

Additional file 2: Clinical stage-specific disability weights and distribution of breast cancer in females in China.

Additional file 3: Age-specific incidence, mortality and survival rates of breast cancer.

Additional file 4: Age-specific number of females and standardized life expectancy
informing subsequent analysis. JW contributed to methodology, data analysis, reviewing preliminary results, and informing subsequent analysis. YL contributed to reviewing preliminary results, resource, and informing subsequent analysis. JFS contributed to conceptualization, resources, methodology, funding acquisition, reviewing preliminary results and informing subsequent analysis. All authors read and approved the final manuscript.

Funding
This work was supported by the National Natural Science Foundation of China (81773521) and a Talent Incentive Plan Sponsored by Cancer Hospital, Chinese Academy of Medical Sciences.

Availability of data and materials
Data are publicly available.

Declarations

Ethics approval and consent to participate
Not applicable. Data are publicly available.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no conflict of interests.

Author details
1 Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 Panjianyuan South Lane, Chaoyang District, Beijing 100021, China. 2 National Central Cancer Registry, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China. 3 Division of Health Information Dissemination, Institute of Medical Information, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 3 Yabaob Road, Chaoyang District, Beijing 100020, China.

Received: 31 December 2021 Accepted: 25 September 2022
Published online: 07 October 2022

References
1. Shi J, Zhang Y, Qu C, Zhang K, Guo L, Dai M, He J. Burden of cancer in China: data on disability-adjusted life years. Zhonghua Yu Fang Yi Xue Za Zhi. 2015;49:365–9.
2. Australian Institute of Health and Welfare 2021. Burden of disease. https://www.aihw.gov.au/reports/australias-health/burden-of-disease. Accessed Jan 12, 2021.
3. Nomura S, Yamamoto Y, Yoneoka D, Haagsma JA, Salomon JA, Ueda P, Mori R, Santomauro D, Vos T, Shibuya K. How do Japanese rate the severity of different diseases and injuries? an assessment of disability weights for 231 health states by 37,318 Japanese respondents. Popul Health Metr. 2021;19:21.
4. Ock M, Park B, Park H, Oh IH, Yoon SJ, Cho B, Jo MW. Disability weights measurement for 289 causes of disease considering disease severity in Korea. J Korean Med Sci. 2019;34:660.
5. Institute for Health Metrics and Evaluation. Global burden of disease project. https://ghdx.healthdata.org/gbd-2019. Accessed Jan 12, 2021.
6. Zhang S, Sun K, Zheng R, Zeng H, Wang S, Chen R, Wei W, He J. Cancer incidence and mortality in China. 2015 J Natl Cancer Center. 2021;2:1–11.
7. Wang L, Zhang Y, Shi JF, Dai M. Disease burden of female breast cancer in China. Zhonghua Liu Xing Bing Xue Za Zhi. 2016;37:970–6.
8. Yan XX, Li Y, Cao MD, Wang H, Liu CC, Wang X, Ren JC, Liang L, Lei L, Peng J, et al. DALYs for breast cancer in China, 2000–2050: trend analysis and prediction based on GBD 2019. Zhonghua Liu Xing Bing Xue Za Zhi. 2021;42:2156–63.
9. Zeng H, Chen W, Zheng R, Zhang S, Ji JS, Zou X, Xia C, Sun K, Yang Z, Li H, et al. Changing cancer survival in China during 2003–15: a pooled analysis of 17 population-based cancer registries. Lancet Glob Health. 2018;6:e55–67.
10. Liao XZ, Shi JF, Liu JS, Huang HY, Guo LW, Zhu YY, Xiao HF, Wang L, Bai YN, Liu GX, et al. Medical and non-medical expenditure for breast cancer diagnosis and treatment in China: a multicenter cross-sectional study. Asia Pac J Clin Oncol. 2018;14:147–78.
11. Shi JF, Shi CL, Yue XP, Huang HY, Wang L, Li J, Lou PA, Mao AY, Dai M. Economic burden of cancer in China during 1996–2014: a systematic review. Chin J Oncol. 2016;38:929–41.
12. Dibden A, Offman J, Duffy SW, Gabe R. Worldwide review and meta-analysis of cohort studies measuring the effect of mammography screening programmes on incidence-based breast cancer mortality. Cancers. 2020;12(4):976.
13. Healthy China Initiative Promotion Committee. Healthy China initiative (2020–2030). https://www.gov.cn/xinwen/2019-07/15/content_5409694.htm. Accessed Jan 12, 2021.
14. Shi J-F, Huang H-Y, Guo L-W, Shi D, Gu X-Y, Liang H, Wang L, Ren J-S, Bai Y-N, Mao A-Y. Quality-of-life and health utility scores for common cancers in China: a multicentre cross-sectional survey. Lancet. 2016;388:529.
15. Wang L, Shi JF, Zhu J, Huang HY, Bai YN, Liu GX, Liao XZ, Mao AY, Ren JS, Sun XL et al. Health-related quality of life and utility scores of patients with breast neoplasms in China: a multicenter cross-sectional survey. Breast. 2018;39:53–62.
16. Zhu J, Wang L, Huang HY, Bai FZ, Li J, Fang Y, Wang Y, Mao AY, Liao XZ, Liu GX et al. Short-term impact of breast cancer screening intervention on health-related quality of life in China: A multicentre cross-sectional survey. Psychooncology. 2019;28:1836–44.
17. Zhu J, Yan XX, Dai M, Chen WQ, Shi JF. Approaches to derive disability weights based on EQ-5D measurement: a systematic review. Chin J Evid Based Med. 2020;20:782–8.
18. Haagsma JA, van Beeck EF, Polinder S, Toet H, Panneman M, Bonsel GJ. The effect of comorbidity on health-related quality of life for injured patients in the first year following injury: comparison of three comorbidity adjustment approaches. Popul Health Metr. 2011;9:10.
19. Verraiche JH, van Houten CM, Ross JS, Schullier AA. The burden of disease of dental anxiety: generic and disease-specific quality of life in patients with and without extreme levels of dental anxiety. Eur J Oral Sci. 2016;124:454–8.
20. Zhao P, Chen WQ. 2009 Chinese cancer registry annual report. Beijing: Military Medical Science Press; 2010.
21. Zhao P, Chen WQ. 2010 Chinese cancer registry annual report. Beijing: Military Medical Science Press; 2011.
22. He J, Zhao P, Chen WQ. 2011 Chinese cancer registry annual report. Beijing: Military Medical Science Press; 2012.
23. He J, Chen WQ. 2012 Chinese cancer registry annual report. Beijing: Military Medical Science Press; 2012.
24. He J, Chen WQ. 2013 Chinese cancer registry annual report. Beijing: Tsinghua University Press; 2017.
25. He J, Chen WQ. 2014 Chinese cancer registry annual report. Beijing: Tsinghua University Press; 2017.
26. He J, Chen WQ. 2015 Chinese cancer registry annual report. Beijing: Tsinghua University Press; 2017.
27. He J, Chen WQ. 2016 Chinese cancer registry annual report. Beijing: Tsinghua University Press; 2017.
28. He J, Chen WQ. 2017 Chinese cancer registry annual report. Beijing: People's Medical Publishing House; 2018.
29. He J, Chen WQ. 2018 Chinese cancer registry annual report. Beijing: People's Medical Publishing House; 2019.
30. National Bureau of Statistics. China Statistical Yearbooks. Available from: https://www.stats.gov.cn/tjsj/ndsj/. Accessed date Jan 12, 2021.
31. United Nations: department of economic and social affairs population dynamics. World Population Prospects 2019. Available from: https://popul ation.un.org/wpp/DataQuery/. Accessed date Jan 12, 2021.
32. Institute for Health Metrics and Evaluation (IHME). Global Burden of Disease Study 2015 (GBD 2015) Reference Life Table. Available from: https://ghdx.healthdata.org/record/ihme-data/gbd-2015-reference-life-table. Accessed date Jan 12, 2021.
33. Guan HJ, Liu GE. Comparison analysis on health related quality of life among urban and rural residents in 4 cities of China. Chin Health Econ. 2015;34:5–12.
34. Gao Y. Development and Health Economic Evaluation of Breast Cancer Screening Strategy Among Chinese Women (master’s thesis). Tianjin: Tianjin Medical University; 2016.
35. Wang Q, Li J, Zheng S, Li JY, Pang Y, Huang R, Zhang DN, Zhang B, Yang H, Xie XM, et al. Breast cancer stage at diagnosis and area-based socioeconomic status: a multicenter 10-year retrospective clinical epidemiological study in China. BMC Cancer. 2012;12:122.
36. Zhang M, Zhong Y, Bao H, Zhao Z, Huang Z, Zhang X, Li C, Zhou M, Wang L, Wu J, et al. Breast cancer screening rates among women aged 20 years and above - China, 2015. China CDC Wkly. 2016;3:267–73.
37. Bao HL, Wang LH, Wang LM, Fang LW, Zhang M, Zhao ZP, Cong S. Study on the coverage of cervical and breast cancer screening among women aged 35–69 years and related impact of socioeconomic factors in China, 2013. Zhonghua Liu Xing Bing Xue Za Zhi. 2018;39:208–12.
38. Zheng R, Zeng H, Zhang S, Chen T, Chen W. National estimates of cancer prevalence in China, 2011. Cancer Lett. 2016;370:33–8.
39. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence – SEER Research Data, 13 Registries, Nov 2019 Sub (1992–2017) – Linked To County Attributes – Time Dependent (1990–2017) Income/Rurality, 1969–2018 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2020, based on the November 2019 submission.
40. World Health Organization. WHO methods and data sources for global burden of disease estimates 2000–2019. Available from: www.who.int/data/gho/data/themes/mortality-and-global-health-estimates/global-health-estimates-leading-causes-of-dalys. Accessed date Jan 12 2021.
41. Ferlay J, Laversanne M, Ervik M, et al. Global Cancer Observatory: Cancer Tomorrow. Available from: https://gco.iarc.fr/tomorrow. Accessed date Jan 12 2021.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.